This headline signals a significant positive development for Bausch + Lomb, potentially de-risking a key pipeline asset. FDA support for the study design increases the likelihood of eventual drug approval, which could drive substantial future revenue for the company.
The FDA's 'supportive in principle' stance for the initial study design of BL1243 is a crucial de-risking event for Bausch + Lomb. This positive feedback increases the probability of a successful clinical trial and eventual market approval for their oral dry AMD drug, a condition with significant unmet medical need. While a 2027 start means commercialization is still years away, this news provides a strong positive signal for the company's long-term growth prospects and pipeline strength. Investors will likely view this as a positive catalyst, potentially leading to an upward re-evaluation of BLCO shares. Key risks include the actual trial results and potential competition.